HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintains a $15 price target.
June 12, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reiterates Buy rating on Praxis Precision Medicine (PRAX) and maintains a $15 price target.
The reiterated Buy rating and maintained $15 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Praxis Precision Medicine (PRAX) in the short term. This news is highly relevant and important for investors in PRAX, as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100